NMN and NR for Adults 65+: What Geriatric Patients Need to Know Before Starting NAD+ Precursors

What NMN and NR do

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors of NAD+, a molecule involved in energy metabolism and cellular processes. The body converts NR into NMN along one route to NAD+. Human studies have measured increases in NAD-related compounds after oral supplementation. [1,2]

A blood NAD+ result and a change in daily function are different measurements. If your goal is walking farther, recovering strength, or managing fatigue, track that outcome directly. A higher laboratory value by itself does not tell you whether getting out of a chair or completing an errand has become easier.

What trials in older adults have found

The studies below help separate the populations, doses, and outcomes that are often grouped together in supplement advertising. These are research regimens, not individual dosing recommendations.

The 2026 study is especially relevant to dose decisions: a substantially higher dose produced a blood metabolite response without a corresponding improvement in the reported physical-performance measures. Taking more should not be treated as a reliable way to improve mobility.

Another frequently cited NMN trial enrolled postmenopausal women with prediabetes and overweight or obesity. It found improved muscle insulin sensitivity over 10 weeks. That is a specific metabolic result in that population, not a reason to replace diabetes treatment or assume the same outcome for every older adult. [5]

Choose the goal before choosing the supplement

“Healthy aging” is broad. A concrete goal makes the decision easier to evaluate.

• Fatigue: Record when it occurs, how long it has lasted, sleep quality, and whether it affects ordinary activities.
• Walking or strength: Note changes in usual walking distance, stair climbing, or rising from a chair. If balance is poor, use a supervised assessment rather than testing your limits alone.
• Diabetes management: Use the glucose and HbA1c plan already established with your clinician.
• General wellness: Consider whether the cost and pill burden fit your priorities alongside food, activity, sleep, and existing treatment.

Fatigue lasting several weeks deserves an assessment. Anemia, thyroid conditions, sleep problems, depression, chronic illness, and medicines can contribute. The National Institute on Aging recommends evaluating the person's history and symptoms to guide examination and testing. [6]

NMN versus NR: compare actual products

Look at the active ingredient and daily amount rather than the size of the capsule or the phrase “NAD booster.” An NR-and-pterostilbene blend is a different intervention from NR alone. NMN capsules, sublingual products, and multi-ingredient powders also should not be treated as equivalent formulations.

When comparing two products, write down:

1. The named ingredient and amount per capsule or scoop.
2. The number of servings in the bottle and the recommended daily serving.
3. All added ingredients, including niacin and botanical extracts.
4. The cost per day at the amount you would actually use.
5. Whether the published study tested that ingredient alone or a specific combination.

For example, an eight-week trial in 120 adults aged 60 to 80 tested NR plus pterostilbene and found increased blood NAD+. It did not compare that combination against NR alone. A separate pterostilbene trial found increased LDL cholesterol with pterostilbene alone, making the added ingredient relevant for someone with high cholesterol. [7,8]

Review medicines and health conditions before starting

Older adults often manage several conditions at once. Use one current list covering prescriptions, nonprescription medicines, vitamins, and supplements. Bring the actual product label to the clinician or pharmacist. [9]

Warfarin and other anticoagulants

If you take warfarin, tell the anticoagulation team before starting or changing a supplement. They can decide whether your INR schedule needs adjustment. For other anticoagulants, the review focuses on the medicine, the added ingredients, kidney function, and bleeding history; an INR schedule is not interchangeable across these drugs. [10]

Do not change an anticoagulant dose because a supplement causes bruising or because a product claims to improve circulation. Report new unexplained bleeding promptly.

Diabetes treatment

Continue prescribed medicines and the established glucose-monitoring plan. Tell your clinician about changes in appetite, meal intake, glucose readings, or gastrointestinal symptoms after adding a product. A favorable insulin-sensitivity result from an NMN study does not specify how to adjust metformin or insulin for an individual. [5]

Cancer treatment

Have the oncology team review supplements before use during treatment or a clinical trial. Cancer medicines differ, and a product that appears harmless on its own can complicate a treatment plan. [11]

PARP inhibitors such as olaparib target enzymes involved in DNA repair and promote PARP-DNA complex formation. They should not be described as working simply by depleting NAD+. Use the actual treatment mechanism and the oncology team's review when assessing any proposed supplement combination. [12]

Kidney or liver disease

Do not select an NMN or NR dose by applying a general “half-dose” rule for age or kidney disease. A dose tested in healthy participants does not provide an individualized adjustment for reduced kidney or liver function. Ask the treating clinician to review whether the product is appropriate alongside your condition, existing medicines, and recent test results. [9]

What to monitor

Use a plan matched to the person and the reason for supplementation. There is no need to adopt a large recurring blood-test panel solely because an online dosing chart lists one.

Avoid changing several supplements at the same time. If a new symptom appears, the dates and product details help the care team assess the cause. Keep the packaging so the exact formulation remains identifiable.

If a product is not helping the goal you agreed to track, reconsider it rather than automatically increasing the dose or adding a second precursor.

Keep supplements on the list during care transitions

Include NMN or NR when moving between primary care, specialists, hospital care, and rehabilitation. A useful handoff records the product name, complete ingredient list, daily amount, start date, reason for use, and any suspected side effects.

After a hospital stay or a major medicine change, review the list again before resuming supplements. Ask which products to continue, hold, or stop, and keep a dated copy that you and your caregiver can access.

Frequently asked questions

What doses have been studied in adults over 65?

Examples include NMN 250 mg/day in older-adult trials and 1,250 mg/day in the 2026 trial. The Martens NR study used 500 mg twice daily in a mixed middle-aged and older population. Those are study doses, not a standard prescription for everyone over 65. [1-4]

Will raising NAD+ improve my strength?

The trials measured different outcomes. Some early NMN results suggested changes in selected muscle-function tests, while the 24-week studies described above did not show significant improvements in their reported physical-performance outcomes. Assess strength and mobility directly rather than using a NAD+ result as a substitute. [1,3,4]

Is there a required time of day?

Follow the particular product's directions and choose a routine you can maintain. The Martens NR trial used morning and evening doses with meals. That is a studied schedule, not a universal requirement for all NAD+ precursor products. [2]

Should I buy a blood NAD+ test?

First ask what the result would change. Research measurements can show a biological response, but decisions about fatigue, mobility, diabetes, or another condition should center on those outcomes and the relevant clinical assessment.

What is NMN's current U.S. supplement status?

FDA concluded in its September 29, 2025 citizen-petition response that NMN was not excluded from the dietary supplement definition under the drug-exclusion provision. This is a classification decision, not a treatment approval for aging or another condition. [13]

References

1. Igarashi et al. NMN supplementation in healthy older men, 2022.
2. Martens et al. Chronic NR supplementation in healthy middle-aged and older adults, 2018.
3. Akasaka et al. NMN in older patients with diabetes and impaired physical performance, 2023.
4. Igarashi et al. High-dose NMN supplementation in older adults: a 24-week randomized trial, 2026.
5. Yoshino et al. NMN increases muscle insulin sensitivity in prediabetic women, 2021.
6. National Institute on Aging: Fatigue in Older Adults.
7. Dellinger et al. Repeat-dose NR and pterostilbene trial, 2017.
8. Riche et al. Pterostilbene on metabolic parameters: randomized trial, 2014.
9. NCCIH: Using Dietary Supplements Wisely.
10. MedlinePlus: Warfarin.
11. National Cancer Institute: Cancer Therapy Interactions With Foods and Dietary Supplements.
12. FDA: Lynparza (olaparib) prescribing information, 2025.
13. FDA response to the NMN citizen petition, September 29, 2025.